A resource for collecting cancer data and biospecimens

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The iCaRe2 is a multi-institutional resource developed by the Fred & Pamela Buffett Cancer Center to gather and manage standardized, longitudinal data and biospecimens from adult cancer patients, high-risk individuals, and normal controls. This initiative focuses on a wide geographical coverage, including small and rural hospitals, to enhance studies on cancer risk factors and to facilitate the development of innovative strategies for prevention, screening, and personalized treatment. The repository supports collaboration among centers with expertise in various cancer-related fields, allowing for comprehensive cohort and population studies.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Diagnosis/history of cancer
* Risk for developing cancer or suspicious clinical findings
* No history of cancer (normal control registry)
* Able to provide informed consent
* 19 years of age or older
* English or Spanish speaking individuals

Exclusion Criteria

* Unable to provide informed consent because of cognitive impairment
* Non-English or non-Spanish speaking individuals

Where it's running

• Advent Health
  Greenwood Village, Colorado, United States Recruiting
• Hartford HealthCare Cancer Institute at Manchester Medical Hospital
  Manchester, Connecticut, United States Recruiting
• Florida Hospital Memorial Medical Center
  Daytona Beach, Florida, United States Recruiting
• Florida Hospital DeLand
  DeLand, Florida, United States Recruiting
• Florida Hospital FISH
  Orange City, Florida, United States Recruiting
• Florida Hospital Flagler
  Palm Coast, Florida, United States Recruiting

Study contacts

• Principal investigator: Kurt Fisher, MD, PhD — University of Nebraska
• Study coordinator: Artem Pachikov
• Email: artem.pachikov@unmc.edu
• Phone: 402-559-0568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Testing MDX2001 for advanced solid tumors

  This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Denver, Colorado and 5 other locations · NCT06239194

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.